NewAmsterdam Pharma (NAMS) Competitors $19.13 +0.58 (+3.13%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$19.79 +0.66 (+3.44%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. RVMD, LNTH, BBIO, TGTX, LEGN, SRPT, TLX, ADMA, BPMC, and VRNAShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Verona Pharma Revolution Medicines (NASDAQ:RVMD) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Do analysts rate RVMD or NAMS? Revolution Medicines presently has a consensus price target of $66.67, indicating a potential upside of 65.10%. NewAmsterdam Pharma has a consensus price target of $43.33, indicating a potential upside of 126.52%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RVMD or NAMS? Revolution Medicines received 71 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.43% of users gave NewAmsterdam Pharma an outperform vote while only 77.17% of users gave Revolution Medicines an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes9877.17% Underperform Votes2922.83% NewAmsterdam PharmaOutperform Votes2796.43% Underperform Votes13.57% Does the media favor RVMD or NAMS? In the previous week, Revolution Medicines had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 23 mentions for Revolution Medicines and 12 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.48 beat Revolution Medicines' score of 1.28 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 16 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RVMD or NAMS? Revolution Medicines has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Is RVMD or NAMS more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% NewAmsterdam Pharma N/A N/A N/A Do institutionals & insiders hold more shares of RVMD or NAMS? 94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, RVMD or NAMS? NewAmsterdam Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$742K10,117.48-$436.37M-$3.57-11.31NewAmsterdam Pharma$45.56M46.11-$176.94M-$2.60-7.36 SummaryNewAmsterdam Pharma beats Revolution Medicines on 10 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04B$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-7.367.4422.5718.48Price / Sales46.11242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book5.476.516.774.25Net Income-$176.94M$143.21M$3.22B$248.23M7 Day Performance9.50%1.97%1.46%0.89%1 Month Performance4.08%6.89%3.98%3.53%1 Year Performance-12.93%-2.52%16.14%5.09% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.1884 of 5 stars$19.13+3.1%$43.33+126.5%-12.3%$2.04B$45.56M-7.364Positive NewsRVMDRevolution Medicines3.7636 of 5 stars$41.47+7.0%$66.67+60.8%+8.3%$7.71B$742,000.00-11.55250Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9711 of 5 stars$102.70+0.9%$129.43+26.0%+56.8%$7.03B$1.53B17.09700Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$35.89-1.2%$53.00+47.7%+49.7%$6.81B$221.90M-12.59400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap UpTGTXTG Therapeutics3.327 of 5 stars$42.03+1.7%$40.67-3.2%+233.2%$6.67B$329.00M-420.26290Upcoming EarningsNews CoveragePositive NewsGap DownLEGNLegend Biotech2.6303 of 5 stars$34.70+1.2%$78.82+127.1%-20.1%$6.37B$627.24M-36.531,070Positive NewsSRPTSarepta Therapeutics4.7345 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownHigh Trading VolumeADMAADMA Biologics1.472 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading VolumeBPMCBlueprint Medicines2.5598 of 5 stars$88.51+1.0%$124.53+40.7%-2.0%$5.66B$508.82M-81.95640Earnings ReportAnalyst ForecastNews CoveragePositive NewsVRNAVerona Pharma2.8962 of 5 stars$68.83+5.1%$78.50+14.0%+366.5%$5.56B$42.28M-35.8530Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Revolution Medicines Alternatives Lantheus Alternatives BridgeBio Pharma Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives ADMA Biologics Alternatives Blueprint Medicines Alternatives Verona Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts